<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="575">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153668</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00284589</org_study_id>
    <nct_id>NCT05153668</nct_id>
  </id_info>
  <brief_title>Everolimus Trial in Laryngotracheal Stenosis</brief_title>
  <official_title>AERO: Adjuvant EveRolimus Outcomes in Laryngotracheal Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subglottic stenosis (obstructing scar in the larynx and trachea) occurs in patients&#xD;
      spontaneously (idiopathic), with autoimmune disease, and after long-term breathing tube&#xD;
      placement and can result in communication disability and high mortality rates due to the&#xD;
      obstructed airway. The proposed Adjuvant EveRolimus Outcomes (AERO) trial is proof-of-concept&#xD;
      study using the immunosuppressant drug, everolimus, to reduce the number of surgeries for&#xD;
      patients with idiopathic Subglottic Stenosis (iSGS). Success with the AERO trial will allow&#xD;
      for everolimus to be used in subsequent larger trials of participants with laryngotracheal&#xD;
      stenosis and could lead to everolimus being the first FDA approved medical treatment for&#xD;
      iSGS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">March 2025</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Peak Expiratory flow in patients with Laryngotracheal Stenosis</measure>
    <time_frame>Baseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, 2 years</time_frame>
    <description>Change in Peak Expiratory flow (L/min) in patients with Laryngotracheal Stenosis will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dilation interval (time between surgery)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Dilation interval (time between surgery) in months will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Voice-related Quality of Life Score</measure>
    <time_frame>Baseline, 1 month, 2 months, 3 months, 6 months, 1 year, 2 years</time_frame>
    <description>Number scale of 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Clinical COPD Questionnaire Quality of Life Score</measure>
    <time_frame>Baseline, 1 month, 2 months, 3 months, 6 months, 1 year, 2 years</time_frame>
    <description>Number scale of 0-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eating Assessment Tool (EAT-10) Swallow Quality of Life Score</measure>
    <time_frame>Baseline, 1 month, 2 months, 3 months, 6 months, 1 year, 2 years</time_frame>
    <description>Number scale of 0-40</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 12-Item Short Form (SF-12) Survey Global Quality of Life Score</measure>
    <time_frame>Baseline, 1 month, 2 months, 3 months, 6 months, 1 year, 2 years</time_frame>
    <description>Number scale of 0-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lumen surface area</measure>
    <time_frame>Baseline and 6 months</time_frame>
    <description>CT Neck will be used to assess change in lumen surface area in millimeters squared (mm^2).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Idiopathic Subglottic Tracheal Stenosis</condition>
  <arm_group>
    <arm_group_label>Adjuvant Everolimus After Surgical Dilation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individuals will take low dose everolimus for 6 weeks after dilation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus Oral Tablet</intervention_name>
    <description>Everolimus 1.5mg by mouth daily will be given for 42 days after dilation surgery.</description>
    <arm_group_label>Adjuvant Everolimus After Surgical Dilation</arm_group_label>
    <other_name>Zortress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Current diagnosis of laryngotracheal stenosis&#xD;
&#xD;
          -  Patient age 18 - 80 years old&#xD;
&#xD;
          -  ECOG performance status of 0 - 1&#xD;
&#xD;
          -  Serum total bilirubin and SGPT (ALT) &lt; 2.0 times the upper limit of normal;&#xD;
&#xD;
          -  Serum creatinine &lt; 2.0 mg/dL;&#xD;
&#xD;
          -  The patient must be able to comprehend and have signed the informed consent.&#xD;
&#xD;
          -  The patient must have documentation of their date of laryngotracheal stenosis&#xD;
             diagnosis and prior medical/surgical history.&#xD;
&#xD;
          -  Participants must have also had a prior suspension microlaryngoscopy with endoscopic&#xD;
             excision of scar and balloon dilation procedure prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of corticosteroids (glucocorticoids) within 7 days of everolimus administration&#xD;
             (except physiologic dose equivalent)&#xD;
&#xD;
          -  Infection requiring treatment with antibiotics, antifungal, or antiviral agents within&#xD;
             7 days of registration&#xD;
&#xD;
          -  Participation in any clinical trial within 21 days of bone marrow collection involving&#xD;
             an investigational drug or device&#xD;
&#xD;
          -  History of malignancy within five years of registration, except adequately treated&#xD;
             basal or squamous cell skin cancer&#xD;
&#xD;
          -  History of an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis,&#xD;
             systemic lupus erythematosus) requiring active systemic treatment. Hypothyroidism&#xD;
             without evidence of Grave's disease or Hashimoto's thyroiditis is permitted.&#xD;
&#xD;
          -  HTLV 1 or 2 positive&#xD;
&#xD;
          -  NYHA class II-IV heart failure within the past 6 months&#xD;
&#xD;
          -  History of organ transplant with use of immunosuppression&#xD;
&#xD;
          -  Current use of immunosuppression&#xD;
&#xD;
          -  Contraindication or documented intolerance to everolimus&#xD;
&#xD;
          -  Women of childbearing potential who are not on highly effective contraception or&#xD;
             abstinent for at least 30 days. Highly effective contraception includes at least two&#xD;
             forms of concurrent contraception (Condoms, oral contraceptives, intrauterine devices,&#xD;
             contraceptive implants).&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding, or wishing to become pregnant are excluded&#xD;
             from this study&#xD;
&#xD;
          -  Current use of cytochrome P450 3A inducers (such as some anticonvulsants, rifampin,&#xD;
             isoniazid, St. John's wort).&#xD;
&#xD;
          -  Current use of cytochrome P450 3A inhibitors (such as azole antifungals,&#xD;
             nondihydropyridine calcium channel blockers, some macrolide antibiotics, grapefruit)&#xD;
             can result in significant interactions&#xD;
&#xD;
          -  Baseline proteinuria as defined by urine dipstick analysis&#xD;
&#xD;
          -  History of angioedema&#xD;
&#xD;
          -  Baseline/continued use of drugs known to be associated with angioedema including&#xD;
             angiotensin converting enzyme inhibitors&#xD;
&#xD;
          -  Significant pulmonary disease independent of laryngotracheal stenosis as defined by&#xD;
             and FEV1/FVC &lt; 10% of the expected value for the patient's age.&#xD;
&#xD;
          -  Evidence of a COVID-19 infection including anosmia, upper respiratory symptoms or&#xD;
             positive test result within the 30 days prior of trial participation.&#xD;
&#xD;
          -  Patients who are not fully vaccinated for COVID 19 for at least 4 weeks prior to study&#xD;
             entry&#xD;
&#xD;
          -  Immunosuppressive therapy within previous 21 days or expected need for&#xD;
             immunosuppressive therapy for the duration of the study&#xD;
&#xD;
          -  Known immunodeficiency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Hillel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Collins</last_name>
    <phone>4432876006</phone>
    <email>shirsh1@jhmi.edu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tracheal Stenosis</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tracheal Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

